Competitive PressuresThe presence of more competitors in Zai Lab's core product market offsets the potential benefits of its products nearing commercialization.
Product RevenueProduct revenues for 1Q25 of $105.7M were below the company-provided consensus estimate of $113.9M and were down ~2.6% QoQ from $108.5M in 4Q24.
Safety ConcernsThere has been an increase in Grade 3+ cytopenias (7-21%), new instances of Grade 3+ interstitial lung disease (ILD, 7%), and a rise in treatment discontinuations (18%).